Should environmental isolates be used in pharmaceutical microbiology?
Are environmental isolates truly beneficial in qualifying microbiological methods? Here EPR summarises Tim Sandle’s recent paper on the debate.
List view / Grid view
News
New data on bivalent COVID-19 booster platform from Moderna
The results indicate that mRNA-1273.211 at the 50 µg dose level induced higher antibody responses than the 50 µg mRNA-1273 booster, even when additional variants of concern were not included in the booster vaccine.
Research team discover new reaction for making tertiary amines
The new chemical reaction, a carbon-hydrogen amination cross-coupling reaction, creates a faster, simpler way of making tertiary amines without the inherent limitations of classic methods.
IRBM to receive EIB funding to expand R&D into COVID-19
IRBM’s goal will be to help ensure a more resilient global response to future epidemics by producing second generation vaccines and treatments for SARS-CoV-2 and new coronaviruses.
Sanofi begins construction of Singapore vaccine facility
The facility is designed around a central unit that comprises several fully digitalised modules, which can produce up to four vaccines simultaneously, regardless of the vaccine technology used.
Achilles Therapeutics expands manufacturing in the UK
The scale up in annual capacity and expansion of Achilles' global clinical manufacturing footprint will see its second site in the UK and first site to be established in the US.
Evusheld reduces risk of symptomatic COVID-19 in high-risk population
Phase III trial shows Evusheld (tixagevimab and cilgavimab) significantly reduces the risk of developing symptomatic COVID-19 in vulnerable populations.
![Samsung Biologics logo on a phone screen [Credit: viewimage/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Samsung-biologics-300x278.jpg)
![Samsung Biologics logo on a phone screen [Credit: viewimage/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Samsung-biologics-e1650536525880.jpg)
Samsung Bioepis fully acquired by Samsung Biologics
After first payment of $1bn to Biogen, Samsung Biologics has now fully acquired Samsung Bioepis.
How should environmental monitoring locations be chosen?
Here, EPR summarises Dr William Whyte’s guidance for formally selecting cleanroom monitoring locations and action levels.
Left-handed gold nanoparticles improve vaccine efficacy by more than 25 percent, finds study
The results of a recent international study suggest that left-handed gold nanoparticles can increase vaccine effectiveness by 25 percent, providing useful adjuvant capabilities.
WuXi Biologics awarded for excellence
WuXi Biologics awarded the Bioprocessing Excellence in Viral Clearance and Safety accolade for the second time at the Asia-Pacific Bioprocessing Excellence Awards (ABEA) 2022 event.
GSK will acquire Sierra Oncology to strengthen haematology arsenal
GlaxoSmithKline has announced the agreed $1.9bn acquisition of biopharmaceutical company Sierra Oncology, which specialises in treatments for rare forms of cancer.
Expanding API manufacturing operations: Cambrex and Asymchem
Cambrex expands API manufacturing capacity at flagship US facility and Asymchem completes construction of two new Chinese API production sites.
Draft guidance to improve US clinical trial diversity
The new clinical trial guidance asks sponsors to submit a Race and Ethnicity Diversity Plan outlining how they plan to enrol participants from underrepresented populations.
Moderna and ROVI face further particulate problems with Spikevax®
A lot of Moderna’s Spikevax® vaccine is being recalled due to particulates, just six months after previous contamination concerns were supposedly solved.
